Literature DB >> 21320834

Meaningful change in cognition in multiple sclerosis: method matters.

L A S Walker1, P D Mendella, A Stewart, M S Freedman, A M Smith.   

Abstract

OBJECTIVE: To determine if different methods of evaluating cognitive change over time yield measurably different outcomes.
METHODS: Twelve cognitively impaired patients with clinically definite Multiple sclerosis (10 relapsing-remitting, 2 secondary progressive) underwent neuropsychological testing (baseline, 6, 12 months). Data was analysed using: t-tests evaluating group differences on individual tests, group differences in composite scores, reliable change analyses at the level of the individual, and comparisons regarding number of tests failed at each time point.
RESULTS: Group t-tests on individual tests yielded no change. When tests were grouped according to theoretical constructs, analyses revealed change in processing speed. Reliable change estimates revealed that 16% of the sample deteriorated. When change was measured with respect to the number of domains affected at each time point, 58% of the sample deteriorated on at least one subtest.
CONCLUSIONS: Methodology has a significant impact on interpretation of longitudinal data. In the same group of subjects, traditional group analyses documented no change in individual test scores or change on a single composite score. Analyses of individual results documented change from 16 to 58% of the sample. Advantages and disadvantages of each method were discussed. Findings have implications for interpretation of longitudinal studies.

Entities:  

Mesh:

Year:  2011        PMID: 21320834     DOI: 10.1017/s0317167100011471

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  3 in total

1.  White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.

Authors:  O T Wiebenga; M M Schoonheim; H E Hulst; G J A Nagtegaal; E M M Strijbis; M D Steenwijk; C H Polman; P J W Pouwels; F Barkhof; J J G Geurts
Journal:  AJNR Am J Neuroradiol       Date:  2016-03-10       Impact factor: 3.825

2.  Cognitive functions over the course of 1 year in multiple sclerosis patients treated with disease modifying therapies.

Authors:  Kathrin S Utz; De-Hyung Lee; Alexandra Lämmer; Anne Waschbisch; Ralf A Linker; Thomas Schenk
Journal:  Ther Adv Neurol Disord       Date:  2016-04-18       Impact factor: 6.570

3.  The presence of cerebral white matter lesions and lower skin microvascular perfusion predicts lower cognitive performance in type 1 diabetes patients with retinopathy but not in healthy controls-A longitudinal study.

Authors:  Anna L Emanuel; Eelco van Duinkerken; Mike P Wattjes; Martin Klein; Frederik Barkhof; Frank J Snoek; Michaela Diamant; Etto C Eringa; Richard G IJzerman; Erik H Serné
Journal:  Microcirculation       Date:  2019-02-22       Impact factor: 2.628

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.